hsa-mir-210 Pancreatic Neoplasms 20360935 Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer hsa-mir-17 Neoplasms 20234369 the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls hsa-mir-21 Neoplasms 20234369 the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls hsa-mir-106a Neoplasms 20234369 the plasma concentrations of miRNAs (miR-17-5p, miR-21, miR-106a, miR-106b) were significantly higher in GC patients than controls hsa-mir-31 Mouth Neoplasms 20233326 plasma miR-31 could be validated a marker of OSCC for diagnostic uses hsa-mir-146a Sepsis 20188071 Serum miR-146a and miR-223 as potential new biomarkers for sepsis hsa-mir-223 Sepsis 20188071 Serum miR-146a and miR-223 as potential new biomarkers for sepsis hsa-mir-195 Breast Neoplasms 20134314 circulating levels of miR-195 and let-7a decreased in cancer patients postoperatively hsa-mir-106a Stomach Neoplasms 20349219 miR-106a:detection of miRNA in peripheral blood may be a novel tool for monitoring circulating tumor cells in patients with gastric cancers hsa-mir-106b Melanoma 20529253 miR-106b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-107 Melanoma 20529253 miR-107:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-1249 Melanoma 20529253 miR-1249:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-125a Melanoma 20529253 miR-125a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-423 Heart Failure 20185794 MiR423-5p as a circulating biomarker for heart failure hsa-mir-17 Stomach Neoplasms 20349219 miR-17:detection of miRNA in peripheral blood may be a novel tool for monitoring circulating tumor cells in patients with gastric cancers hsa-mir-208a Myocardium 20395621 miR-208:plasma miR-208 is a biomarker of myocardial injury hsa-mir-499a Myocardial Infarction 20395621 Plasma microRNA 499 as a biomarker of acute myocardial infarction hsa-mir-17 Melanoma 20529253 miR-17:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-181a-2 Melanoma 20529253 miR-181a-2*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-183 Melanoma 20529253 miR-183*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-186 Melanoma 20529253 miR-186:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-18a Melanoma 20529253 miR-18a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-18a Melanoma 20529253 miR-18a*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-199a-1 Melanoma 20529253 miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-199a-2 Melanoma 20529253 miR-199a-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-20a Melanoma 20529253 miR-20a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-20b Melanoma 20529253 miR-20b:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-214 Melanoma 20529253 miR-214:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-216a Melanoma 20529253 miR-216a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-217 Melanoma 20529253 miR-217:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-22 Melanoma 20529253 miR-22*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-221 Melanoma 20529253 miR-221*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-30a Melanoma 20529253 miR-30a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-30e Melanoma 20529253 miR-30e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-328 Melanoma 20529253 miR-328:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-330 Melanoma 20529253 miR-330-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-342 Melanoma 20529253 miR-342-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-361 Melanoma 20529253 miR-361-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-362 Melanoma 20529253 miR-362-3p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-362 Melanoma 20529253 miR-362-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-365a Melanoma 20529253 miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-365b Melanoma 20529253 miR-365:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-378a Melanoma 20529253 miR-378*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-422a Melanoma 20529253 miR-422a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-452 Melanoma 20529253 miR-452:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-501 Melanoma 20529253 miR-501-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-509-3 Melanoma 20529253 miR-509-3-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-517a Melanoma 20529253 miR-517*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-518e Melanoma 20529253 miR-518e*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-519b Melanoma 20529253 miR-519b-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-550a-1 Melanoma 20529253 miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-550a-2 Melanoma 20529253 miR-550*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-584 Melanoma 20529253 miR-584:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-593 Melanoma 20529253 miR-593*:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-621 Melanoma 20529253 miR-621:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-625 Melanoma 20529253 miR-625:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-646 Melanoma 20529253 miR-646:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-664 Melanoma 20529253 miR-664:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-767 Melanoma 20529253 miR-767-5p:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-99a Melanoma 20529253 miR-99a:21 miRNAs that were downregulated in blood cells of melanoma patients and 30 miRNAs that were upregulated in blood cells of melanoma patients hsa-mir-200a Pancreatic Neoplasms 20551052 miR-200a:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility hsa-mir-200b Pancreatic Neoplasms 20551052 miR-200b:The elevated serum levels of miR-200a and miR-200b in most patients with pancreatic cancer could have diagnostic utility hsa-mir-486 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-20b Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-21 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-24-1 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-24-2 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-15a Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-126 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-191 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-197 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-223 Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-320a Diabetes Mellitus, Type 2 20651284 decreased in plasma hsa-mir-29a Scleroderma, Systemic 21129921 Circulating miR-29a levels in patients with scleroderma spectrum disorder hsa-mir-29a Scleroderma, Localized 21129921 Circulating miR-29a levels in patients with scleroderma spectrum disorder hsa-mir-223 Liver Neoplasms 21154767 in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls hsa-mir-122 Liver Neoplasms 21154767 in serum, miR-21, miR-122, and miR-223 were significantly higher in patients with HCC than those in healthy controls hsa-mir-126 Heart Failure 21157109 The plasma concentration of miR-126 was negatively correlated with age and NYHA class, and could be a useful biomarker for heart failure hsa-mir-96 Urinary Bladder Neoplasms 21166959 MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. hsa-mir-183 Urinary Bladder Neoplasms 21166959 MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. hsa-mir-1254-1 Carcinoma, Non-Small-Cell Lung 21258252 miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls. The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation. hsa-mir-574 Carcinoma, Non-Small-Cell Lung 21258252 miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung Cancer. The expression of hsa-miR-1254 and hsa-miR-574-5p was significantly increased in the early-stage NSCLC samples with respect to the controls. The utility of miR-1254 and miR-574-5p serum-based biomarkers as minimally invasive screening and triage tools for subsequent diagnostic evaluation warrants additional validation. hsa-mir-221 Melanoma 21273047 Malignant melanoma patients had significantly higher miR-221 levels than healthy controls in serum. hsa-mir-16-1 Carcinoma, Hepatocellular 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). hsa-mir-16-2 Carcinoma, Hepatocellular 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). hsa-mir-199a-1 Carcinoma, Hepatocellular 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). hsa-mir-199a-2 Carcinoma, Hepatocellular 21278583 Serum levels of miR-16 and miR-199a were significantly lower in HCC than in CLD patients or control subjects (P<0.01). hsa-mir-221 Carcinoma, Hepatocellular 21295551 Serum miR-221, upregulated in HCC, can provide predictive significance for prognosis of HCC patients. hsa-mir-200a Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-200b Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-200c Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-205 Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-429 Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-192 Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-141 Lupus Erythematosus, Systemic 21372198 The serum levels of miR-200a, miR-200b, miR-200c, miR-429, miR-205 and miR-192, and urinary miR-200a, miR-200c, miR-141, miR-429 and miR-192 of SLE patients were lower than those of controls. hsa-mir-92a-1 Lymphoma 21383985 Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. hsa-mir-92a-2 Lymphoma 21383985 Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma. hsa-mir-20a Leukemia, Lymphocytic, Chronic, B-Cell 21460253 circulating miR-20a correlates reliably with diagnosis-to-treatment time. hsa-mir-1-1 Muscular Dystrophy, Duchenne 21479190 the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased hsa-mir-1-2 Muscular Dystrophy, Duchenne 21479190 the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased hsa-mir-133a-1 Muscular Dystrophy, Duchenne 21479190 the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased hsa-mir-133a-2 Muscular Dystrophy, Duchenne 21479190 the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased hsa-mir-206 Muscular Dystrophy, Duchenne 21479190 the serum levels of several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased hsa-mir-126 Mesothelioma 21483773 Levels of miR-126 in serum, and its levels in patients' serum in association with a specific marker of MPM, SMRPs, correlate with subjects at high risk to develop malignant pleural mesothelioma (MPM). hsa-mir-9-1 Wounds and Injuries 21538484 Upregulated in in serum hsa-mir-9-2 Wounds and Injuries 21538484 Upregulated in in serum hsa-mir-9-3 Wounds and Injuries 21538484 Upregulated in in serum hsa-mir-146b Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-mir-221 Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-let-7a-1 Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-let-7a-2 Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-let-7a-3 Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-mir-155 Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-mir-17 Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-mir-27a Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-mir-106a Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-mir-29c Carcinoma, Non-Small-Cell Lung 21544802 The expression of miR-146b, miR-221, let-7a, miR-155, miR-17-5p, miR-27a and miR-106a were significantly reduced in the serum of NSCLC cases while miR-29c was significantly increased. hsa-let-7b Carcinoma, Non-Small-Cell Lung 21544802 Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients. hsa-mir-223 Carcinoma, Non-Small-Cell Lung 21544802 Reduced plasma expression of let-7b was modestly associated with worse cancer-specific mortality in all patients and reduced serum expression of miR-223 was modestly associated with cancer-specific mortality in stage IA/B patients. hsa-mir-590 Alzheimer Disease 21548758 Decreased relative expression levels of hsa-miR-590-3p in blood cells was observed in patients with AD versus controls. hnRNP-A1 and its transcription regulatory factor miR-590-3p are disregulated in patients with AD, and the hnRNP-A1 rs7967622 C/C genotype is likely a risk factor for FTLD in male populations. hsa-mir-124-1 Cerebral Infarction 21551949 Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction. hsa-mir-124-2 Cerebral Infarction 21551949 Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction. hsa-mir-124-3 Cerebral Infarction 21551949 Plasma concentrations of miR-124 were significantly elevated at 6 h, and remained elevated at 48 h after middle cerebral artery occlusion introduction. hsa-mir-342 Glioblastoma 21561454 miR-342-3p: downregulated in the peripheral blood of glioblastoma patients. hsa-mir-128-1 Glioblastoma 21561454 upregulated in the peripheral blood of glioblastoma patients. hsa-mir-128-2 Glioblastoma 21561454 upregulated in the peripheral blood of glioblastoma patients. hsa-let-7a-1 Myelodysplastic Syndromes 21602527 Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. hsa-let-7a-2 Myelodysplastic Syndromes 21602527 Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. hsa-let-7a-3 Myelodysplastic Syndromes 21602527 Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. hsa-mir-16-1 Myelodysplastic Syndromes 21602527 Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. hsa-mir-16-2 Myelodysplastic Syndromes 21602527 Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. hsa-mir-122 Hepatitis B, Chronic 21606975 The serum level of miR-122 strongly correlates with serum ALT activity and with necroinflammatory activity in patients with CHC and elevated ALT levels, but not with fibrosis stage and functional capacity of the liver hsa-mir-21 Carcinoma, Non-Small-Cell Lung 21627863 Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05). hsa-mir-223 Stomach Neoplasms 21628394 miRNA-223 Promotes Gastric Cancer Invasion and Metastasis by Targeting Tumor Suppressor EPB41L3. hsa-mir-1-1 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. hsa-mir-1-2 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. hsa-mir-133a-1 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. hsa-mir-133a-2 Myocardial Infarction 21642241 Increased MicroRNA-1 and MicroRNA-133a Levels in Serum of Patients With Cardiovascular Disease Indicate Myocardial Damage. hsa-mir-31 Carcinoma, Squamous Cell 21658006 miR-31 was up-regulated in 77.8% of the ESCC tissues. Serum miR-31 levels in ESCC patients were significantly higher than in normal controls (P<0.001). hsa-mir-21 Carcinoma, Squamous Cell 21673684 the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164). hsa-mir-375 Carcinoma, Squamous Cell 21673684 the plasma level of miR-21 was significantly higher (P=0.0218) and that of miR-375 (P=0.0052) was significantly lower in ESCC patients than controls. (2) The high plasma miR-21 levels reflected tumour levels in all cases (100%). The plasma level of miR-21 was significantly reduced in postoperative samples (P=0.0058). (3) On validation analysis, the plasma level of miR-21 tended to be higher in ESCC patients (P=0.0649), while that of miR-375 was significantly lower (P<0.0001) and the miR-21/miR-375 ratio was significantly higher (P<0.0001) in ESCC patients than in controls. The value of the area under the receiver-operating characteristic curve (AUC) was 0.816 for the miR-21/miR-375 ratio assay. Patients with a high plasma level of miR-21 tended to have greater vascular invasion (P=0.1554) and to show a high correlation with recurrence (P=0.0164). hsa-mir-146a Glomerulonephritis, IGA 21694443 The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated. hsa-mir-155 Glomerulonephritis, IGA 21694443 The expression levels of miR-146a and miR-155 in kidney biopsy and urine from patients with IgA nephropathy were elevated. hsa-mir-210 Kidney Failure, Acute 21700819 Circulating miR-210 predicts survival in critically ill patients with acute kidney injury. hsa-mir-21 Carcinoma, Non-Small-Cell Lung 21721011 serum miR-21 expression was an independent prognostic factor for NSCLC patients. hsa-mir-34a Schizophrenia 21738743 peripheral blood miR-34a was differentially expressed between cases and controls in both the learning and the testing set. hsa-mir-21 Carcinoma, Hepatocellular 21749846 In the 10-patient group, plasma microRNA-21 levels significantly diminished after surgery compared with the pre-operative values (p=0.0125). Plasma microRNA-21 level in the 126 patients with hepatocellular carcinoma was significantly higher than in patients with chronic hepatitis and healthy volunteers (p<0.0001, p<0.0001, respectively). ROC analysis of plasma microRNA-21 yielded an AUC of 0.773 with 61.1% sensitivity and 83.3% specificity when differentiating hepatocellular carcinoma from chronic hepatitis, and an AUC of 0.953 with 87.3% sensitivity and 92.0% specificity when differentiating hepatocellular carcinoma from healthy volunteers. hsa-mir-26a-1 Cerebral Hemorrhage 21764522 Circulating miR-26a is a potential predictors and therapeutic targets for non-hypertensive ICH (intracerebral hemorrhage). hsa-mir-26a-2 Cerebral Hemorrhage 21764522 Circulating miR-26a is a potential predictors and therapeutic targets for non-hypertensive ICH (intracerebral hemorrhage). hsa-mir-21 Multiple Sclerosis 21875645 In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls. hsa-mir-146a Multiple Sclerosis 21875645 In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls. hsa-mir-146b Multiple Sclerosis 21875645 In peripheral mononuclear cells, a statistically significant increased expression of miR-21, miR-146a and -b was observed in relapsing remitting (RR)MS patients as compared with controls. hsa-mir-133a-1 Myocardial Infarction 21881276 The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples. hsa-mir-133a-2 Myocardial Infarction 21881276 The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples. hsa-mir-133b Myocardial Infarction 21881276 The miR-133 levels in plasma from AMI patients exhibited a 4.4-fold increase compared with control subjects (p=0.006). Moreover, the increased miR-133 levels in whole blood were comparable with those in plasma samples. hsa-mir-328 Myocardial Infarction 21881276 miR-328 levels in plasma and whole blood of AMI patients were markedly increased by 10.9-fold and 16.1-fold, respectively, compared to those in control subjects (p=0.033 and p<0.001). hsa-mir-142 Scleroderma, Systemic 21883400 Serum miR-142-3p levels in patients with SSc (systemic sclerosis) were significantly higher than in patients with SSD (scleroderma spectrum disorder), SLE (systemic lupus erythematosus) or DM (dermatomyositis), and healthy control groups. Patients with increased miR-142-3p levels tended to have a short sublingual frenulum. hsa-mir-122 Fatty Liver, Alcoholic 21886843 Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis. hsa-mir-34a Fatty Liver, Alcoholic 21886843 Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis. hsa-mir-16-1 Fatty Liver, Alcoholic 21886843 Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis. hsa-mir-16-2 Fatty Liver, Alcoholic 21886843 Serum levels of miR-122, miR-34a and miR-16 were significantly higher in NAFLD patients than in controls. miR-122 and miR-34a levels positively correlated with disease severity from simple steatosis to steatohepatitis. hsa-mir-155 Lung Neoplasms 21904633 The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001). hsa-mir-197 Lung Neoplasms 21904633 The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001). hsa-mir-182 Lung Neoplasms 21904633 The levels of miR-155, miR-197, and miR-182 in the plasma of lung cancer including stage I patients were significantly elevated compared with controls (P<0.001). The combination of these 3 miRNAs yielded 81.33% sensitivity and 86.76% specificity in discriminating lung cancer patients from controls. The levels of miR-155 and miR-197 were higher in the plasma from lung cancer patients with metastasis than in those without metastasis (P<0.05) and were significantly decreased in responsive patients during chemotherapy (P<0.001). hsa-mir-19a Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level. hsa-mir-19b-1 Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level. hsa-mir-19b-2 Lymphoma 21910161 Compared with normal cani ne peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level. hsa-mir-17 Lymphoma 21910161 miR-17-5p: Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show an increased expression level. hsa-mir-203 Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level. hsa-mir-218-1 Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level. hsa-mir-218-2 Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level. hsa-mir-181a-1 Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level. hsa-mir-181a-2 Lymphoma 21910161 Compared with normal canine peripheral blood mononuclear cells (PBMC) and normal lymph nodes (LN), the miRNA show a decreased expression level. hsa-mir-134 Pulmonary Embolism 21943159 Plasma miRNA-134 (miR-134) level was significantly higher in the APE patients than in the healthy controls or non-APE patients. The ROC curve showed that plasma miR-134 was a specific diagnostic predictor of APE with an area under the curve of 0.833 (95% confidence interval, 0.737 to 0.929; P<0.001). The findings indicated that plasma miR-134 could be an important biomarker for the diagnosis of APE. hsa-mir-20a Myocardial Infarction 21949348 deregulated between blood of patients with Unstable Angina and patients with Myocardial Infarction. hsa-mir-20a Angina, Unstable 21949348 deregulated between blood of patients with Unstable Angina and patients with Myocardial Infarction. hsa-mir-326 Multiple Sclerosis 21949733 Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS (relapsing remitting multiple sclerosis) patients compared to healthy controls. hsa-mir-29a Tuberculosis, Pulmonary 21998423 Circulating miR-29a might have great potential to serve as a marker for detection of active pulmonary tuberculosis infection. hsa-mir-335 Parkinson Disease 22003392 miR-335: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-374a Parkinson Disease 22003392 miR-374a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-199b Parkinson Disease 22003392 miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-126 Parkinson Disease 22003392 miR-126*: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-151a Parkinson Disease 22003392 miR-151-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-151a Parkinson Disease 22003392 miR-151-5p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-126 Parkinson Disease 22003392 miR-126: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-29b-1 Parkinson Disease 22003392 miR-29b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-29b-2 Parkinson Disease 22003392 miR-29b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-147a Parkinson Disease 22003392 miR-147: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-28 Parkinson Disease 22003392 miR-28-5p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-30b Parkinson Disease 22003392 miR-30b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-374b Parkinson Disease 22003392 miR-374b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-19b-1 Parkinson Disease 22003392 miR-19b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-19b-2 Parkinson Disease 22003392 miR-19b: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-30c-1 Parkinson Disease 22003392 miR-30c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-30c-2 Parkinson Disease 22003392 miR-30c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-29c Parkinson Disease 22003392 miR-29c: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-301a Parkinson Disease 22003392 miR-301a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-26a-1 Parkinson Disease 22003392 miR-26a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-26a-2 Parkinson Disease 22003392 miR-26a: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-199a-1 Parkinson Disease 22003392 miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-199a-2 Parkinson Disease 22003392 miR-199a-3p/miR-199b-3p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-199a-1 Parkinson Disease 22003392 miR-199a-5p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-199a-2 Parkinson Disease 22003392 miR-199a-5p: differentially expressed in PBMCs (peripheral blood mononuclear cells) of PD patients and controls. hsa-mir-126 Carcinoma, Non-Small-Cell Lung 22009180 There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients. hsa-mir-183 Carcinoma, Non-Small-Cell Lung 22009180 There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients. hsa-mir-222 Carcinoma, Non-Small-Cell Lung 22009180 There was statistical difference in the serum levels for hsa-miR-126, hsa-miR-183, and hsa-miR-222 between the controls and the Stage IV patients (metastatic non-small-cell lung cancer). It also showed statistical difference for hsa-miR-126 and hsa-miR-183 between the Stage I/II patients and Stage IV patients. hsa-mir-29a Colorectal Neoplasms 22018950 Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. hsa-mir-122 Drug-Induced Liver Injury 22045675 Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients. hsa-mir-192 Drug-Induced Liver Injury 22045675 Serum miR-122 and miR-192 were substantially higher in APAP-ALI patients. hsa-mir-21 Hepatitis C 22066022 The serum miR-21 level is a marker for necroinflammatory activity, but does not differ between patients with HCV and HCV-induced HCC. hsa-mir-210 Pre-Eclampsia 22095477 Serum expression level of miR-210 was up-regulated in preeclampsia patients. hsa-mir-152 Pre-Eclampsia 22095477 Serum expression level of mir-152 was down-regulated in preeclampsia patients. hsa-mir-423 Heart Failure 22120965 miR-423-5p: significantly increased serum level hsa-mir-320a Heart Failure 22120965 significantly increased serum level hsa-mir-22 Heart Failure 22120965 significantly increased serum level hsa-mir-92b Heart Failure 22120965 significantly increased serum level hsa-mir-1266 Psoriasis 22133505 Increased serum levels of miR-1266 in patients with psoriasis vulgaris. hsa-mir-137 Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-181c Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-9-1 Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-9-2 Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-9-3 Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-29a Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-29b-1 Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-29b-2 Alzheimer Disease 22155483 Blood serum expressio level of these miRNAs may be non-invasive biomarkers for Alzheimer's disease. hsa-mir-24-1 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-24-2 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-26a-1 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-26a-2 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-181a-1 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-181a-2 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-342 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-574 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-130b Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-103a-1 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-103b-1 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-103a-2 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-103b-2 Pre-Eclampsia 22187671 Seven microRNAs, namely miR-24, miR-26a, miR-103, miR-130b, miR-181a, miR-342-3p, and miR-574-5p, were validated to be elevated in plasma from severe pre-eclamptic pregnancies by using real-time quantitative stem-loop reverse-transcription polymerase chain reaction analysis. hsa-mir-614 Multiple Sclerosis 22231906 Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. hsa-mir-572 Multiple Sclerosis 22231906 Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. hsa-mir-648 Multiple Sclerosis 22231906 Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. hsa-mir-422a Multiple Sclerosis 22231906 Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. hsa-mir-22 Multiple Sclerosis 22231906 Six plasma miRNA (miR-614, miR-572, miR-648, miR-1826, miR-422a and miR-22) that were significantly up-regulated and one plasma miRNA (miR-1979) that was significantly down-regulated in MS individuals. hsa-mir-218-1 Uterine Cervical Neoplasms 22237456 Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. hsa-mir-218-2 Uterine Cervical Neoplasms 22237456 Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor invasion. hsa-mir-122 Hepatitis B 22239527 Serum miR-122 levels are strongly correlated with HBs antigen. hsa-mir-141 Prostatic Neoplasms 22240788 Circulating miR-141 and miR-375 have association with metastatic prostate cancer. hsa-mir-375 Prostatic Neoplasms 22240788 Circulating miR-141 and miR-375 have association with metastatic prostate cancer. hsa-mir-4306 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-202 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-4257 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-1323 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-335 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-497 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-106b Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-922 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-516b-1 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-mir-516b-2 Breast Neoplasms 22242178 The miRNA is up-regulated in whole blood of breast cancer patients hsa-let-7a-1 Breast Neoplasms 22242178 let-7a* is up-regulated in whole blood of breast cancer patients hsa-let-7a-2 Breast Neoplasms 22242178 let-7a* is up-regulated in whole blood of breast cancer patients hsa-let-7a-3 Breast Neoplasms 22242178 let-7a* is up-regulated in whole blood of breast cancer patients hsa-mir-718 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-625 Breast Neoplasms 22242178 miR-625* is down-regulated in whole blood of breast cancer patients hsa-mir-1471 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-193a Breast Neoplasms 22242178 miR-193a-3p is down-regulated in whole blood of breast cancer patients hsa-mir-182 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-1915 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-107 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-2355 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-3186 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-24-1 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-24-2 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-3130-1 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-3130-2 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-526a-1 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-526a-2 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-1469 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-874 Breast Neoplasms 22242178 The miRNA is down-regulated in whole blood of breast cancer patients hsa-mir-499a Myocardial Infarction 22252325 Serum miR-499 and hs-cTnT provided comparable diagnostic value with areas under the ROC curves of 0.97. The reclassification index of miR-499 to a clinical model including several risk factors and hs-cTnT was not significant (P = 0.15). hsa-mir-16-1 Breast Neoplasms 22298638 Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls. hsa-mir-16-2 Breast Neoplasms 22298638 Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls. hsa-mir-25 Breast Neoplasms 22298638 Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls. hsa-mir-222 Breast Neoplasms 22298638 Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls. hsa-mir-324 Breast Neoplasms 22298638 Serum miR-16, miR-25, miR-222 and miR-324-3p that were consistently differentially expressed between breast cancer cases and controls. hsa-mir-20a Breast Neoplasms 22350790 Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively. hsa-mir-21 Breast Neoplasms 22350790 Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively. hsa-mir-214 Breast Neoplasms 22350790 Levels of preoperative serum miR-20a and miR-21 were significantly higher in patients with breast cancer and benign disease than in healthy women (p = 0.0001), but only serum miR-214 could discriminate malignant from benign tumors and healthy controls (p = 0.0001) with an area under the curve of 0.878 and 0.883 in ROC analysis, respectively. hsa-mir-21 Esophageal Neoplasms 22354855 Serum concentration of miRNA-21 in ESCC patients was significantly higher than that in healthy controls (P?